Actively Recruiting
A Study of AMDX-2011P in Participants With CAA
Led by Amydis Inc. · Updated on 2026-02-13
25
Participants Needed
1
Research Sites
125 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
CONDITIONS
Official Title
A Study of AMDX-2011P in Participants With CAA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of hereditary CAA or probable/definite symptomatic or asymptomatic sporadic CAA confirmed by genetic testing or modified Boston neuroradiological criteria with at least one prior brain MRI
- Abnormality consistent with CAA on past MRI
- Generally in good health
You will not qualify if you...
- Any physical or psychological condition likely to prevent study completion
- Clinically significant laboratory abnormalities
- Active malignancy or cancer history within past 5 years except fully removed non-melanoma skin cancer or low-grade cervical intraepithelial neoplasia
- Prolonged QTcF (>450 ms for males, >470 ms for females), cardiac arrhythmia, or significant ECG abnormalities
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Associated Retina Consultants
Phoenix, Arizona, United States, 85020
Actively Recruiting
Research Team
M
Matthew Lehman
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here